| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
OTTAWA, Ontario—Orion Biotechnology Canada Ltd. recently announced new preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Seven days after inoculation, the mice were randomized to receive intraperitoneal treatment with OB-002; a murine anti-PD-1 antibody; an anti-CTLA-4 antibody; OB-002 plus an anti-PD-1; OB-002 plus an anti-CTLA-4; OB-002, an anti-PD-1 and an anti-CTLA-4; or a saline placebo.
 
The OB-002 and the saline placebo were administered five times per week, and the anti-PD-1 and anti-CTLA-4 antibodies were given every third day. Treatment with OB-0020 or the anti-PD-1 antibody alone led to equivalent delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed when animals received combinations of OB-0020 and the anti-PD-1 or anti-CTLA-4 antibodies.
 
“These data confirm and build upon previous experiments conducted in the CT-26 model. This is impressive, as treatment was only started seven days after implantation of the tumor cells. This new study clearly demonstrates that OB-002 has activity alone, or in combination with other immunotherapy agents, in the treatment of colorectal cancer and provides guidance as to how future clinical trials should be designed,” said Dr. Ian McGowan, chief medical officer for Orion Biotechnology.
 
Added Mark Groper, president and CEO of Orion Biotechnology: “We are delighted by these new data that confirm and extend our initial observations on the activity of OB-002 in colorectal cancer and provide a compelling rationale for moving this unique product into clinical trials as quickly as possible.”

Related Topics

Published In

Volume 15 - Issue 8 | August 2019

August 2019

August 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue